Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC

Lung cancer has the highest incidence and mortality rates among the malignant tumor types world-wide. Platinum-based chemotherapy is the main treatment for advanced non-small-cell lung cancer (NSCLC), and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have greatly improved t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Oncol
Main Authors: Pan, Chi, Duan, Huijie, Wu, Yinan, Zhu, Chunpeng, Yi, Chenghao, Duan, Yin, Lu, Demin, Guo, Cheng, Wu, Deqi, Wang, Yanyan, Fu, Xianhua, Xu, Jing, Chen, Yiding, Luo, Meng, Tian, Wei, Pan, Tao, Xu, Wenhong, Zhang, Suzhan, Huang, Jianjin
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2020
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7473755/
https://ncbi.nlm.nih.gov/pubmed/32945394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2020.5103
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki